Intent Solutions, MAP team up to study compliance in patients with addiction

Intent Solutions and MAP Health Management will launch their pilot program as early as March.

Intent Solutions and MAP Health Management have inked a deal to monitor medication adherence in people diagnosed with substance use disorder. The duo could launch their pilot program as early as next month.

Intent Solutions has designed a smart, portable medication dispenser that also collects data on the user. Dubbed TAD, the biometric device dispenses a correct dose of medication at the right time and can connect to mobile devices to tell users when to take their medication.

Meanwhile, MAP’s platform is designed to support providers of behavioral health and addiction treatment. Of the patients using MAP’s platform, 84% have a co-occurring mental or behavioral health disorder as well as substance use disorder, according to a statement.

Event

Join the world's top medtech executives virtually for the leading event in medtech — The Virtual MedTech Conference by AdvaMed

Expect the same high-quality education, world-class speakers and valuable business development in a virtual format. Experience more of the conference with on demand content and partnering, as well as livestreamed sessions.

The partnership will begin with a pilot program, in which patients whose risk of relapse is already being tracked by MAP’s platform will be given a TAD device, according to the statement. TAD will transmit real-time data on when a patient takes or misses a dose to MAP’s system. MAP will then relay the over- or underuse information to collaborative care networks, who can then intervene and improve clinical outcomes.

"The number one factor in improving outcomes is early intervention. Putting the TAD into the hands of people recovering from addiction who are prescribed medication will greatly enable MAP to better inform treatment providers, family members, and insurance carriers who are at high risk for relapse and readmission resulting from the lack of medication compliance," said MAP CEO Jacob Levenson, in the statement.

Other players working on medication adherence include Philips, which developed the Medido countertop dispenser. In a 1,379-patient study, 96% of the participants met an adherence rate from the World Health Organization. And in April last year, the FDA rejected Otsuka's pill with an ingestible sensor for use with its adherence tracking system.

Suggested Articles

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.

Cellex has announced plans to develop a rapid coronavirus test that people can fully perform at home, from sample collection to result, using an app.

More than 20 states either don’t release or have incomplete data on the rapid antigen tests now considered key to containing the coronavirus.